![A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis](https://docusalut.com/bitstream/handle/20.500.13003/10098/000551966000001.pdf.jpg?sequence=4&isAllowed=y)
A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis
![Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial - The Lancet Rheumatology Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial - The Lancet Rheumatology](https://www.thelancet.com/cms/attachment/7d233120-27e9-495e-9a42-381e0b87fb0c/gr1.gif)
Safety and efficacy of rituximab in systemic sclerosis (DESIRES): open-label extension of a double-blind, investigators-initiated, randomised, placebo-controlled trial - The Lancet Rheumatology
![How to process data from clinical trials and their open label extensions PhUSE, Berlin, October 2010 Thomas Grupe and Stephanie Bartsch, Clinical Data. - ppt download How to process data from clinical trials and their open label extensions PhUSE, Berlin, October 2010 Thomas Grupe and Stephanie Bartsch, Clinical Data. - ppt download](https://images.slideplayer.com/23/6590870/slides/slide_3.jpg)
How to process data from clinical trials and their open label extensions PhUSE, Berlin, October 2010 Thomas Grupe and Stephanie Bartsch, Clinical Data. - ppt download
![Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia | BMC Psychiatry | Full Text Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia | BMC Psychiatry | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs12888-016-0879-5/MediaObjects/12888_2016_879_Fig1_HTML.gif)
Long-term health-related quality of life improvements among patients treated with lurasidone: results from the open-label extension of a switch trial in schizophrenia | BMC Psychiatry | Full Text
![Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren's Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial - ACR Meeting Abstracts Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren's Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial - ACR Meeting Abstracts](https://acrabstracts.org/wp-content/uploads/2019/08/GTUOHVCE-693522-1-ANY.png)
Efficacy and Safety of Abatacept in Patients with Early Active Primary Sjögren's Syndrome – Open-label Extension Phase of a Randomized Controlled Phase III Trial - ACR Meeting Abstracts
![MARINE: Multi-Center, PlAcebo-Controlled, Randomized, Double-BlINd, 12- week study with an open-label Extension (NCT01047683) - Triglyceride Forum MARINE: Multi-Center, PlAcebo-Controlled, Randomized, Double-BlINd, 12- week study with an open-label Extension (NCT01047683) - Triglyceride Forum](https://www.triglycerideforum.org/wp-content/uploads/2022/08/MARINE_AL.png)
MARINE: Multi-Center, PlAcebo-Controlled, Randomized, Double-BlINd, 12- week study with an open-label Extension (NCT01047683) - Triglyceride Forum
![Uncontrolled Extensions of Clinical Trials and the Use of External Controls—Scoping Opportunities and Methods - Wang - 2022 - Clinical Pharmacology & Therapeutics - Wiley Online Library Uncontrolled Extensions of Clinical Trials and the Use of External Controls—Scoping Opportunities and Methods - Wang - 2022 - Clinical Pharmacology & Therapeutics - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/43fdedc4-12f0-43f4-b7ab-4e40b80d0822/cpt2346-fig-0001-m.jpg)
Uncontrolled Extensions of Clinical Trials and the Use of External Controls—Scoping Opportunities and Methods - Wang - 2022 - Clinical Pharmacology & Therapeutics - Wiley Online Library
![Study design schematic for the open-label extension study. AE, adverse... | Download Scientific Diagram Study design schematic for the open-label extension study. AE, adverse... | Download Scientific Diagram](https://www.researchgate.net/publication/233396586/figure/fig4/AS:289187577253918@1445959099647/Figure1-Study-design-schematic-for-the-open-label-extension-study-AE-adverse-event-IR.png)
Study design schematic for the open-label extension study. AE, adverse... | Download Scientific Diagram
![Summary of Other Studies, Open-Label Extensions - Clinical Review Report: Telotristat (Xermelo) - NCBI Bookshelf Summary of Other Studies, Open-Label Extensions - Clinical Review Report: Telotristat (Xermelo) - NCBI Bookshelf](https://www.ncbi.nlm.nih.gov/books/NBK546770/bin/clapp7f1.jpg)
Summary of Other Studies, Open-Label Extensions - Clinical Review Report: Telotristat (Xermelo) - NCBI Bookshelf
![Flow chart showing the study design of the open-label extension phase... | Download Scientific Diagram Flow chart showing the study design of the open-label extension phase... | Download Scientific Diagram](https://www.researchgate.net/publication/337470199/figure/fig2/AS:836912487088133@1576546894872/Flow-chart-showing-the-study-design-of-the-open-label-extension-phase-OLE-of-the.png)
Flow chart showing the study design of the open-label extension phase... | Download Scientific Diagram
![Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology](https://www.thelancet.com/cms/attachment/2883e24f-ded5-4447-96b4-db02193741ca/gr1.gif)
Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial - The Lancet Neurology
![Randomized controlled trial and open-label extension study designs.... | Download Scientific Diagram Randomized controlled trial and open-label extension study designs.... | Download Scientific Diagram](https://www.researchgate.net/publication/265174624/figure/fig1/AS:267323823095810@1440746374062/Randomized-controlled-trial-and-open-label-extension-study-designs-aNonresponders-20.png)